Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EBT: 2017-2025

Historic EBT for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $9.2 million.

  • Puma Biotechnology's EBT fell 55.15% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year increase of 25.33%. This contributed to the annual value of $24.1 million for FY2024, which is 6.29% up from last year.
  • Puma Biotechnology's EBT amounted to $9.2 million in Q3 2025, which was up 49.93% from $6.2 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's EBT peaked at $20.6 million during Q3 2024, and registered a low of -$44.6 million during Q3 2021.
  • Its 3-year average for EBT is $5.9 million, with a median of $6.0 million in 2023.
  • Its EBT has fluctuated over the past 5 years, first spiked by 2,150.85% in 2023, then tumbled by 396.83% in 2024.
  • Puma Biotechnology's EBT (Quarterly) stood at $4.4 million in 2021, then crashed by 219.75% to -$5.3 million in 2022, then surged by 341.04% to $12.8 million in 2023, then declined by 4.42% to $12.2 million in 2024, then slumped by 55.15% to $9.2 million in 2025.
  • Its EBT stands at $9.2 million for Q3 2025, versus $6.2 million for Q2 2025 and $3.3 million for Q1 2025.